Request Appointment
353 East 68th StreetNew York, NY 10065
Overview of Dr. Feldman
Dr. Darren Feldman is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from University of Maryland School of Medicine and has been in practice 15 years. He specializes in genitourinary oncology and hematologic oncology and is experienced in testicular neoplasms, kidney cancer, and urologic oncology
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
New York Presbyterian Hospital (Cornell Campus)Chief Residency, Internal Medicine, 2004 - 2005
NYU Grossman School of MedicineInternship, Internal Medicine, 2001 - 2004
University of Maryland School of MedicineClass of 2001
Certifications & Licensure
FL State Medical License 2021 - Present
CT State Medical License 2023 - 2027
NJ State Medical License 2019 - 2027
NY State Medical License 2004 - 2027
NC State Medical License 2020 - 2022
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
- CMS Meaningful Use Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2016-2017
Clinical Trials
- Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) Start of enrollment: 2011 Jul 01
- Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls Start of enrollment: 2011 Oct 11
- Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Publications & Presentations
PubMed
- Stereotactic radiosurgery and multimodal integration approaches for germ cell tumor brain relapse.Chengcheng Gui, Samuel A Funt, Lillian A Boe, Alok Deshane, Yao Yu
Journal of Neuro-Oncology. 2026-06-18 - How to Optimize Treatment for Patients With Poor-Risk Testicular Cancer.Noah Richardson, Alok K Tewari, Patrizia Giannatempo, Michael F Basin, Amedeo Nuzzo
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2026-06-01 - Real-World Evidence of Treatment Patterns, Time to Real-World Progression, and Overall Survival of Patients With Testicular Germ Cell Tumors Receiving Palliative Chemo...Darren R Feldman, Patrick Gagnon-Sanschagrin, Jessica Maitland, Kana Yokoji, Annie Guérin
Cancer Medicine. 2026-06-01
Journal Articles
- Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised ...Toni K Choueiri, Olwen Hahn, Thomas Olencki, Eric J Small, Shaker Dakhil, Darren R Feldman, European Journal of Cancer
Lectures
- Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for in...2019 ASCO Annual Meeting - 6/1/2019
- Hematologic Malignancies Arising in Patients with Germ Cell Tumors: Secondary Somatic Differentiation of Hematopoietic Malignancies from Germ Cell Precursors2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patien...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
- Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]September 2018
- Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival UpdateApril 2018
Press Mentions
DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAMMarch 22nd, 2023- Monrol Is Partnering with Telix Pharmaceuticals, Supplying Lutetium Nca Lu 177 for the Manufacturing of Clinical Doses for the Phase II STARLITE 2 Study at MSK and Manufacturing Clinical Doses for Telix’s Phase III ZIRCON TrialMay 10th, 2022
- Cabozantinib Improves Quality-Adjusted Survival in Advanced RCCOctober 23rd, 2020
Grant Support
- Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterSLOAN-KETTERING INST CAN RESEARCH2019–2032
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
